Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Meta and Apple team up to make Muse AI models run better on Macs

October 15, 2026

Calgary Stampeders need help to reach CFL playoffs

October 15, 2026

Flintstones vitamins, Aleve and Claritin tablets hit in new recall

October 15, 2026

Sony made a $5,900 gold-plated Walkman MP3 player

October 15, 2026

Fisheries sector fund gets $300 million extension from Ottawa, Atlantic provinces

October 15, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Gene Therapy Market Report 2026-2034 – CRISPR and AAV Technologies Propel Gene Therapy Advancements; Global Market Growing at 12.27% CAGR
Press Release

Gene Therapy Market Report 2026-2034 – CRISPR and AAV Technologies Propel Gene Therapy Advancements; Global Market Growing at 12.27% CAGR

By News RoomApril 16, 20263 Mins Read
Gene Therapy Market Report 2026-2034 – CRISPR and AAV Technologies Propel Gene Therapy Advancements; Global Market Growing at 12.27% CAGR
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, April 16, 2026 (GLOBE NEWSWIRE) — The “Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2026-2034” has been added to ResearchAndMarkets.com’s offering.

The global gene therapy market size is projected to expand significantly, with an estimated value of USD 19.3 billion by 2034, growing at a CAGR of 12.27% from 2026-2034. This growth is propelled by the increasing prevalence of genetic disorders and the advancements in gene therapy technologies. North America leads the market, holding a 56% share in 2025, driven by its sophisticated healthcare infrastructure, significant research investments, and regulatory frameworks that encourage innovation.

Gene therapy is gaining traction due to its potential to treat diseases like cystic fibrosis, hemophilia, and cancer by addressing the genetic root causes. Innovations in technologies such as CRISPR-Cas9, viral vectors, and next-generation sequencing are enhancing the efficacy and safety of gene therapy, shortening research durations, and improving clinical trial success rates. Governments and regulatory agencies are playing supportive roles by providing streamlined approval procedures and incentives, which are encouraging further development of gene therapies, especially for rare and complex diseases.

The United States stands as a vital market segment due to its high incidence of genetic and chronic conditions. The launch of groundbreaking treatments, like Orchard Therapeutics’ Lenmeldy for MLD, emphasizes the transformative potential of gene therapies. These therapies, priced at $4.25 million, are being rolled out across specialized treatment centers, supported by innovative reimbursement models.

Key market trends include advancements in viral vector technology, crucial for delivering therapeutic genes into patient cells. Viral vectors like AAVs and lentiviruses, due to their targeted delivery capabilities, are pivotal in enhancing treatment safety and efficacy. Research continues to push boundaries, exploring larger genetic payloads and expanding treatable disorder scopes.

Investments in gene therapy research and development are intensifying, with funds like the Gene Therapy Innovation Fund supporting academic advancements. Pharmaceutical firms are acquiring startups and expanding their R&D efforts to accelerate innovation, further boosting market growth prospects.

Regionally, North America dominates due to its strategic collaborations, health infrastructure, and advanced medical technology adoption. Europe’s gene therapy market is expanding with regulatory advancements and research collaborations focusing on therapy pipelines, especially in oncology and cardiovascular diseases. In the Asia Pacific, increasing governmental and private investments stimulate regional market expansion, with countries like China, India, and Japan leading the charge.

Latin America is experiencing rapid growth due to technological adoption and regulatory improvements. Meanwhile, the Middle East and Africa are seeing significant advances due to government-backed initiatives and partnerships focusing on rare genetic disorder treatments.

Key Attributes

Report Attribute Details
No. of Pages 140
Forecast Period 2025-2034
Estimated Market Value (USD) in 2025 $6.6 Billion
Forecasted Market Value (USD) by 2034 $19.3 Billion
Compound Annual Growth Rate 12.2%
Regions Covered Global

Companies Featured

  • Abeona Therapeutics Inc.
  • Adverum Biotechnologies Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio Inc.
  • Gilead Sciences Inc.
  • Mustang Bio
  • Novartis AG
  • Orchard Therapeutics plc
  • Roche Holding AG
  • Sangamo Therapeutics
  • uniQure NV

For more information about this report visit https://www.researchandmarkets.com/r/ddvivj

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

vineyard vines Returns as Official Style of the Head Of The Charles® Regatta

Bigger & Better Than Ever: Laxmi & Chef Kunal Kapur Return With ‘Diwali Delights’ Season 2

2026 Chery International User Summit to Kick Off: LUXEED Set for Global Brand Launch

Going Asset Management Wins Capital’s Excellence Fund Award, Harnessing Technology to Enhance the Long-Term Value of Assets

Alation Honors 2026 AI Radicals Award Winners at revAlation

Supported Employment: Helping Individuals Build Meaningful Careers

“The Carbon Pursuit of Happiness” Premieres October 10: A New Chapter for In-Depth Dialogue on Health and Humanity

Evolution Metals & Technologies Corp. Raises Fiscal 2026 Revenue Guidance 62% at Midpoint to 11 Million and Reaffirms 460 Million Fiscal 2027 Outlook

Ufunded Launches “Spotlight” Series, Documenting the Minds Shaping Modern Trading

Editors Picks

Calgary Stampeders need help to reach CFL playoffs

October 15, 2026

Flintstones vitamins, Aleve and Claritin tablets hit in new recall

October 15, 2026

Sony made a $5,900 gold-plated Walkman MP3 player

October 15, 2026

Fisheries sector fund gets $300 million extension from Ottawa, Atlantic provinces

October 15, 2026

Latest News

Friends don’t let friends feed their data to AI agents

October 15, 2026

As bond yields rise, how to pick between a variable or fixed rate mortgage?

October 15, 2026

Carney says he expects nations, including U.S., to stay out of Alberta vote

October 15, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version